Recessive congenital methemoglobinemia: a systematic review of reported cases (2026)

Peer-Reviewed Study · Neven J, Beyltjens T, Meuwissen M, De Bisschop B, Bouziotis J, van den Akker M · February 4, 2026

Neven J et al., 2026-02-04: Systematic review of every reported case of recessive congenital methemoglobinemia, stating that methylene blue, ascorbic acid or riboflavin reduce cyanosis but do not change neurological outcomes.

Treatment with methylene blue, ascorbic acid, or riboflavin can reduce cyanosis, but does not affect neurological outcomes.

Neven J et al., 2026-02-04: Systematic review of every reported case of recessive congenital methemoglobinemia, stating that methylene blue, ascorbic acid or riboflavin reduce cyanosis but do not change neurological outcomes. C4. Study type: systematic review of published cases plus the authors' own case (University Hospital Antwerp, Belgium). No trial; N is the count of all reported cases, which is not stated in the abstract text captured. Distinguishes type I (isolated cyanosis) from type II (with severe neurocognitive impairment), both from NADH-cytochrome b5 reductase (CYB5R3) deficiency. Funder and conflicts not stated in the PubMed record. Bearing: it is the strongest current statement that methylene blue addresses the cyanosis and not the neurology, which is exactly the chronic-use limit the claim asks about. Orphanet J Rare Dis 2026 (volume/pages not yet assigned in the PubMed record). Study type: review.